Alternative therapies and future intervention for treatment of membranous nephropathy

Abhijit V. Kshirsagar, Patrick H. Nachman, Ronald J. Falk

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Despite a multitude of investigation over the last 2 decades, the treatment of membranous nephropathy remains both controversial and suboptimal. Recent progress in the molecular pathways of inflammation and immunologic regulation holds the promise of offering futuristic alternatives and/or supplements to the standard regimen of glucocorticoids and alkylating agents. Several potential points of intervention along the path of disease development and expression have been identified-modulation of the immune response to the pathogenetic antigen; inactivation of the inflammatory pathways responsible for B and T cell activation; blockade of pathogenetic antibody formation by B and T cells; blockade of the complement cascade; blockade of lipid peroxidation of glomerular basement membrane components; and blockade of renal fibrosis resulting from proteinuria, lipiduria, and/or inflammation. These points of intervention form the basis for our discussion of such varied potential therapies for membranous nephropathy as: vaccines, inhibitors of tissue plasminogen activator, humanized monoclonal antibodies, mycophenolate mofetil, pentoxifylline, and others.

Original languageEnglish (US)
Pages (from-to)362-372
Number of pages11
JournalSeminars in nephrology
Issue number4
StatePublished - Jul 2003
Externally publishedYes

Bibliographical note

Copyright 2018 Elsevier B.V., All rights reserved.


Dive into the research topics of 'Alternative therapies and future intervention for treatment of membranous nephropathy'. Together they form a unique fingerprint.

Cite this